Sun Pharmaceuticals Industries Downgraded to 'Hold' by MarketsMOJO, Despite Strong Growth and Performance
Sun Pharmaceuticals Industries, a leading player in the pharmaceuticals and drugs industry, has been downgraded to a 'Hold' by MarketsMojo due to its low Debt to Equity ratio. However, the company has shown healthy long-term growth and positive results in the last four quarters. The stock is currently in a Mildly Bullish range and has consistently outperformed the BSE 500 index. With a high institutional holding and a market cap of Rs 4,43,649 cr, it is the largest company in the sector. However, the stock is currently trading at an expensive valuation and investors should carefully consider all factors before making any investment decisions.
Sun Pharmaceuticals Industries, a leading player in the pharmaceuticals and drugs industry, has recently been downgraded to a 'Hold' by MarketsMOJO on November 4, 2024. This decision was based on various factors, including the company's low Debt to Equity ratio, which is currently at 0 times on average.However, despite this downgrade, Sun Pharmaceuticals Industries has shown healthy long-term growth with an annual growth rate of 10.05% in Net Sales and 17.28% in Operating profit. The company has also declared positive results for the last four consecutive quarters, with its highest Operating Cash Flow at Rs 12,134.98 Cr and Return on Capital Employed at 18.48%.
Technically, the stock is currently in a Mildly Bullish range, with multiple factors such as MACD, KST, and DOW indicating a bullish trend. Additionally, the company has a high institutional holding of 36.63%, which shows that these investors have better capabilities and resources to analyze the fundamentals of the company compared to retail investors.
Sun Pharmaceuticals Industries has also consistently generated returns over the last three years, outperforming the BSE 500 index in each of the last three annual periods. With a market cap of Rs 4,43,649 cr, it is the largest company in the sector, constituting 19.00% of the entire industry. Its annual sales of Rs 50,307.74 cr make up 12.58% of the industry.
However, with a ROE of 16.2, the stock is currently trading at a very expensive valuation with a 6.3 Price to Book Value. It is also trading at a premium compared to its average historical valuations. Although the stock has generated a return of 58.58% in the last year, its profits have only risen by 25%, resulting in a PEG ratio of 1.6.
In conclusion, while Sun Pharmaceuticals Industries has shown strong growth and performance in the past, the recent downgrade by MarketsMOJO suggests that investors should hold off on buying the stock at its current valuation. It is important to carefully consider all factors before making any investment decisions.
{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)
{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)
Related Stock Links
- {{stockdata.stock.stock_name.value}} Analysis
- {{stockdata.stock.stock_name.value}} Technicals
- {{stockdata.stock.stock_name.value}} Quality
- {{stockdata.stock.stock_name.value}} Valuation
- {{stockdata.stock.stock_name.value}} Financial Trend
- {{stockdata.stock.stock_name.value}} Return Analysis
- {{stockdata.stock.stock_name.value}} Price Analysis
- {{stockdata.stock.stock_name.value}} Quarterly Result Analysis
- {{stockdata.stock.stock_name.value}} Half-Yearly Result Analysis
- {{stockdata.stock.stock_name.value}} Nine Monthly Result Analysis
- {{stockdata.stock.stock_name.value}} Annual Results
- {{stockdata.stock.stock_name.value}} Balance Sheet
- {{stockdata.stock.stock_name.value}} Profit & Loss
- {{stockdata.stock.stock_name.value}} Cash Flow
- {{stockdata.stock.stock_name.value}} News
- {{stockdata.stock.stock_name.value}} Announcements
- {{stockdata.stock.stock_name.value}} Share Holding
- {{stockdata.stock.stock_name.value}} Peer Comparison
Our weekly and monthly stock recommendations are here
Loading...
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Target Price
{{sm.target_price }}
({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
₹{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News
Sun Pharmaceutical Industries Sees Notable Surge in Derivatives Open Interest Amid Market Volatility
Sun Pharmaceutical Industries Sees Notable Surge in Derivatives Open Interest Amid Market Volatility
Most Read
